Well-Funded Seres Races To Be First To Market With A Microbiome Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
After raising $143 million from an IPO in June, Seres Therapeutics is hoping its lead development candidate SER-109, in Phase II for Clostridium difficile, could be the first microbiome-based drug to reach the market.
You may also be interested in...
Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials
As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.